Vaccination for the Prevention of Group B <i>Streptococcus</i> Infection in Nonpregnant Adults

Dauby, Nicolás

doi:10.1001/jamainternmed.2019.1590

Cited by 2 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there is no clinical evidence that antibodies can prevent GBS infection in adults, healthy and infected older adults are able to produce anti-GBS CPS antibodies. This has been shown both in vaccine trials and following GBS infection [34]. The development of a GBS6 vaccine as a new preventive strategy could potentially prevent these infections in at-risk adults as 97% of the serotypes identified in our study are included in the GBS6 vaccine.…”

Section: Discussionmentioning

confidence: 60%

“…Administered during pregnancy, vaccines aim to protect newborns by transplacental transfer of specific antibodies against these polysaccharides [33]. A hexavalent polysaccharide (GBS6) conjugate vaccine, containing the 6 serotypes responsible for 98% of invasive infections in neonates and adults (Ia, Ib, II, III, IV, and V), is being evaluated in healthy adults after encouraging protective effects have been demonstrated in animals [34]. Although there is no clinical evidence that antibodies can prevent GBS infection in adults, healthy and infected older adults are able to produce anti-GBS CPS antibodies.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Invasive group B Streptococcus among non-pregnant adults in Brussels-Capital Region, 2005–2019

Graux

Hites

Martiny

et al. 2020

Eur J Clin Microbiol Infect Dis

Self Cite

View full text Add to dashboard Cite

To assess the incidence, clinical, microbiological features and outcome of invasive Streptococcus agalactiae (GBS) infections in non-pregnant adults in three tertiary hospitals of the Brussels-Capital Region. All bacterial cultures positive for GBS, from 2005 to 2019 from 3 hospitals of the Brussels-Capital Region, were extracted, and only cases of invasive diseases were included. Medical files were retrospectively retrieved for risk factors, clinical manifestations and outcome and also antibiotic-susceptibility testing and GBS serotypes. Incidence rates were calculated based on the hospitals catchment populations. A total of 337 cases of GBS-invasive infections were included. The incidence of invasive GBS for the 3 hospitals increased from 3.7 to 8.2 cases per 100.000 inhabitants between 2009 and 2018 (p = 0.04). The most frequently identified risk factors were diabetes (36.8%), obesity (35.0%), cancer (21.7%), renal disease (20.8%), and advanced age (≥ 65 years; 47.2%). Isolated bacteremia (22%), osteoarticular infection (21.4%), abscesses (13.9%), and skin and soft tissue infections (18.4%) were the most frequent manifestations. Intensive care unit admission was required in 21.7% and overall mortality was 9.4%. All strains remained susceptible to penicillin over the years. Up to 20% of strains were resistant to clindamycin. Serotypes Ia, Ib, II, III, IV, and V represented 96.8% of the available serotypes (60/62). As reported in several countries, invasive GBS disease in non-pregnant adults represents an increasing burden, particularly among diabetic, obese, and elderly patients. Almost all serotypes identified are included in the upcoming hexavalent GBS conjugate vaccine.

show abstract

Section: Discussionmentioning

confidence: 60%

Section: Discussionmentioning

confidence: 99%

Invasive group B Streptococcus among non-pregnant adults in Brussels-Capital Region, 2005–2019

Graux

Hites

Martiny

et al. 2020

Eur J Clin Microbiol Infect Dis

Self Cite

View full text Add to dashboard Cite

show abstract

Group B Streptococcus Infections in Non-Pregnant Adults, Italy, 2015–2019

Imperi,

Gherardi,

Alfarone

et al. 2024

Pathogens

View full text Add to dashboard Cite

Group B Streptococcus (GBS, Streptococcus agalactiae) is a pathogen of increasing importance in adults. Severe and invasive cases in non-pregnant adults were collected during the period 2015–2019 by voluntary-based surveillance. In total, 108 GBS strains were phenotypically and genotypically characterized for the serotype, antimicrobial resistance, pili, surface protein genes, and the hyper-virulent adhesin hvgA. Patients were divided into two age groups: adults (18–64 years; n = 32) and older adults (≥65 years; n = 72). The average age was 70.8 years, with a male/female ratio of 1.7. Most isolates were recovered from cases of bacteremia (blood, n = 93), and a higher frequency of invasive GBS infections (iGBS) was found among older adults (66.7%). Serotype III was the most frequent (n = 41, 38%), followed by type Ia and type V (n = 20 each, 18.5%). Serotypes Ia, Ib, II, III, IV, and V accounted for all but one isolates (99.1%). The iGBS isolates were universally susceptible to penicillin, while the prevalence of resistance to clindamycin, erythromycin, tetracycline, and high-level gentamicin resistance was 26.8%, 24.1%, 85.2%, and 5.5%, respectively, with the predominance of the erm(B) gene for macrolide resistance and the tet(M) gene for tetracycline resistance. The associations between the serotypes/antimicrobial resistance/virulence traits underlined the increasing importance of serotype III and its contribution to antimicrobial resistance as well as the steady increase over time of serotype IV. This nationwide study confirmed the need for monitoring the GBS epidemiology in non-pregnant adults through continuous surveillance of GBS infections.

show abstract

Vaccination for the Prevention of Group B Streptococcus Infection in Nonpregnant Adults

Cited by 2 publications

References 6 publications

Invasive group B Streptococcus among non-pregnant adults in Brussels-Capital Region, 2005–2019

Invasive group B Streptococcus among non-pregnant adults in Brussels-Capital Region, 2005–2019

Group B Streptococcus Infections in Non-Pregnant Adults, Italy, 2015–2019

Contact Info

Product

Resources

About